C-VUVEOxitope Pharma
S100A4, OxPL, monoclonal antibodies
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-VUVE
C-VUVEC-VUVES100A4, OxPL, monoclonal antibodies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Oxitope Pharma S100A4, OxPL, monoclonal antibodies
Calluna Pharma is a clinical-stage biotechnology company focused on inflammatory and fibrotic diseases. The company was formed from the merger of Oxitope Pharma and Arxx Therapeutics and develops selective antibodies targeting upstream innate immune amplifiers. Its pipeline includes CAL101 for idiopathic pulmonary fibrosis and CAL103 targeting oxidized phospholipids.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Oxitope Pharma — Translational · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic